Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Solid Tumor/Phase INCT ID: NCT01953926
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-615
This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Massachusetts General Hospital
Overall PI: Geoffrey Shapiro, MD, PhD,
Dana-Farber Cancer Institute
Site-responsible Investigators: James Mier, MD,
Beth Israel Deaconess Medical CenterDejan Juric, MD,
Massachusetts General Hospital
Contacts: Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Dana-Farber Cancer Institute:
Andrew Wolanski, 617-632-6623,
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100